January 2nd 2025
Just 60% received detectable antibodies for 2 FDA-approved vaccines, possibly pointing out a need for additional doses to reach protective levels against disease.
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More